TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Cohorts 1 and 2: chronic genotype 1 or 3 HCV infection~* Cohort 3: chronic genotype 1 or 4 HCV infection~* HCV RNA ≥ 10\^4 IU/mL at screening~* Screening labs within defined thresholds~* Cirrhosis determination at screening~Key Exclusion Criteria:~* Females who are pregnant or nursing or males who have a pregnant partner~* Prior null response to pegylated interferon (Peg-IFN)+RBV therapy (Cohorts 1 and 2) or for individuals with cirrhosis, prior treatment failure with IFN-based therapy not resulting from treatment intolerance (Cohort 3)~* Current of prior history of hepatic decompensation~* Infection with hepatitis B virus (HBV) or HIV~* History of clinically significant illness (including psychiatric or cardiac) or any other medical disorder that may interfere with individual's treatment and/or adherence to the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF 200 mg + RBV 200 mg (Cohort 1) (Type: EXPERIMENTAL): Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
- SOF 400 mg + RBV 200 mg (Cohort 2) (Type: EXPERIMENTAL): Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
- LDV/SOF (Cohort 3) (Type: EXPERIMENTAL): Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult female, age 18 years or older~2. Prior diagnosis of breast cancer~3. Willing to participate in this study and given written informed consent~4. AST, ALT, BUN, Cr not more than double the normal values~5. Subjects of childbearing potential must be willing to undergo a pregnancy test prior to enrolment~Exclusion Criteria:~1. Pregnancy (subjects with a positive pregnancy test at baseline screening period or who are planning to become pregnant during the study period)~2. Breastfeeding (subjects in lactation)~3. No biopsy tissue sample can be provided for HER2 expression detection~4. Subjects with pacemakers~5. Hepatitis B virus infection (including carriers) at screening, ie hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody (anti-HCV) positive, or acquired immunodeficiency disease (HIV) infected, or serum syphilis positive person~6. Abnormal liver function during baseline screening period : AST or ALT\> 2 times the upper limit of normal value (ULN), if the marginal increase of a single index is judged as having no clinical significance by the investigator, it can be retested during the screening period. Once, if ≤ 2 times ULN after retesting, consider enrolling).~7. Impaired renal function during screening: serum creatinine or urea nitrogen \> 1.5 times ULN.~8. Within 4 months prior to the baseline screening period , myocardial infarction or other cardiac events requiring hospitalization (unstable angina, etc.), cerebrovascular accident, transient ischemic attack, acute congestive Heart failure or severe arrhythmia (ventricular arrhythmia, atrioventricular block above II)~9. Subjects with pulmonary embolism or deep vein thrombosis~10. Various infections that the investigators consider unsuitable for study, including but not limited to patients with various infections requiring further treatment, such as urinary tract infections, respiratory infections, and diabetic foot infections.~11. Patients with abnormal thyroid function during baseline screening period (including but not limited to active hyperthyroidism, hypothyroidism or Hashimoto's thyroiditis)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Injection of 99mTc-NM-02 (Type: EXPERIMENTAL): All breast cancer patients recruited to the study will be administered 3-12 MBq/kg of 99m-Tc-NM-02 (99m-Tc labeled anti-HER2 sdAb) in a single dose injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have completed all assessments of SPD476-301 or SPD476-302 End of Study/Early Withdrawal Visit~* Subjects who did not achieve remission at the End of Study/Early Withdrawal Visits in Study 301 or 302 will be eligible to enter the Acute Phase; subjects who did achieve remission at the End of Study Visits in Study 301 or 302 will be eligible to enter directly into the Maintenance Phase~* Women of childbearing potential must use an acceptable contraceptive method while on study treatment~Exclusion Criteria:~* Subjects who withdrew from Study 301 or 302 before Study Visit 3, or who withdrew due to a possible or probably related severe adverse event or serious adverse event are not eligible to enter this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Patients both sexes~* Age between 30 and 60 years~* Metabolic Syndrome according to the IDF criteria:~* Waist circumference Man ≥90 cm, Woman ≥80 cm; and two of the following criteria:~* High density lipoprotein Man ≤40 mg/dL, Woman ≤50 mg/dL;~* Fasting glucose ≥100 mg/dL;~* Triglycerides ≥150 mg/dL;~* Blood pressure ≥130/85 mmHg~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to ursolic acid o calcined magnesia~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Previous treatment for the metabolic syndrome components~* Body Mass Index ≥39.9 kg/m2~* Fasting glucose ≥126 mg/dL~* Triglycerides ≥500 mg/dL~* Total cholesterol ≥240 mg/dL~* Low density lipoprotein (c-LDL) ≥190 mg/dL~* Blood Pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ursolic acid (Type: EXPERIMENTAL): Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Pantoprazole in Children With GERD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Endoscopically proven GERD diagnosed within 6 months before study entry.~* Weight must be equal to or over 8.3 kg; for subjects 6 years or greater, weight must be equal to or under 25 kg~Exclusion Criteria:~* History of GI disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption, Eosinophilic esophagitis~* Subjects 6-11 years old unable to swallow tablets

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of military enlistment between August 1, 1990 and July 31, 1991, and deployment for 30 consecutive days to:~  * Persian Gulf waters and adjacent land areas,~ * Other global locations, or,~ * U.S. only. 1990-1991 enlistment status:~ * Active duty~ * National Guard~ * Reserves~Exclusion Criteria:~* HIV/AIDS~* Pregnant Women~* Active Duty Military Personnel~* Children~* Incarceration

- Gender: ALL
- Minimum Age: 34 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- Carnosine treatment group (Type: ACTIVE_COMPARATOR): Carnosine treatment group
- Placebo control group (Type: PLACEBO_COMPARATOR): Placebo control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Investigation of the GORE® Drug-Coated PTA Balloon Catheter (GORE® DCB Catheter)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PAD patients with Rutherford Class 2 - 4~* De novo or restenotic lesions, including total occlusions of the SFA/PA~* 1 lesion which may include one or more regions of luminal narrowing ≥70% with a total combined lesion length between 30 - 150mm and a reference vessel diameter of 4 - 6mm~* 1 patent tibial or peroneal artery~Exclusion Criteria:~* Surgical or endovascular access in the Target limb/vessel within the previous 30 days~* Prior treatment of the Target lesion with PTA within 90 days or any prior treatment with drug-coated balloon~* Prior treatment of the Target vessel with stenting or bypass~* Iliac artery inflow lesions that cannot be successfully treated during the Index procedure~* Acute or subacute thrombus or arterial aneurysm in Target limb~* Severe calcification that renders the Target lesion non-dilatable~* Acute or chronic renal dysfunction (serum creatinine ≥2.5 mg/dL)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Coated Balloon (Type: EXPERIMENTAL): Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing total pancreatectomy and islet auto-transplantation.~* Patients ages 21 to 64 years old~Exclusion Criteria:~* Preexisting diabetes~* Use of acetaminophen during study period, which interferes with CGM sensor function~* Any medical condition requiring corticosteroids~* Severe Psychiatric disease or developmental delays, that might interfere with the ability to provide informed consent~* Any other medical condition which in the opinion of the investigators impairs the person's ability to safely participate in the trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
- Closed Loop Insulin (Type: EXPERIMENTAL): Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy elderly subjects ≥65 years,~2. Individuals willing to provide written informed consent,~3. Individuals in good health,~4. Individuals willing to allow for their serum samples to be stored beyond the study period.~Exclusion Criteria:~1. Individuals not able to understand and follow study procedures,~2. History of any significant illness,~3. History of any serious chronic medical condition or progressive disease,~4. Presence of medically significant cancer,~5. Known or suspected impairment/alteration of immune function,~6. Presence of any progressive or severe neurologic disorder,~7. Presence of any bleeding disorders or conditions that prolongs bleeding time,~8. History of allergy to vaccine components,~9. Receipt of any other investigational product within 30 days prior to entry into the study,~10. History of previous H5N1 vaccination,~11. Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,~12. Receipt of any other vaccine within 2 weeks prior to entry into the study~13. Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,~14. Body mass index (BMI) ≥ 35 kg/m2,~15. History of drug or alcohol abuse,~16. Any planned surgery during study period,~17. Individuals conducting the study and their immediate family members,~18. Individuals with behavioral or cognitive impairment or psychiatric diseases.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- aH5N1c - High dose (Type: EXPERIMENTAL): None
- aH5N1c - Low dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between the ages of 18 and 70 years admitted to a general medicine service.~2. A known history of type 2 diabetes mellitus \> 3 months, receiving either diet alone or any combination of oral antidiabetic agents (sulfonylureas, metformin, thiazolidinediones).~3. Subjects must have an admission blood glucose \> 140 mg and \< 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~Exclusion Criteria:~1. Subjects with increased blood glucose concentration, but without a known history of diabetes.~2. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria \[57\].~3. Patients with known HIV, acute critical or surgical illness and/or expected to require admission to a critical care unit (ICU, CCU), corticosteroid therapy, or to undergo surgery during the hospitalization course.~4. Patients with clinically relevant hepatic disease or impaired renal function, as shown by a serum creatinine ≥3.0.~5. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~6. Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.~7. Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sliding scale regular insulin (Type: ACTIVE_COMPARATOR): sliding scale insulin given acqhs
- glargine insulin and glulisine insulin (Type: ACTIVE_COMPARATOR): glargine basal insulin once a day with prandial glulisine insulin tid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1) Adults (18 to 80 years old):~1. within 72 hours of their hospitalization for infection with Severe Acute Respiratory Syndrome - Corona Virus - 2 (SARS-CoV-2), AND,~2. within 72 hours of the latest Polymerase Chain Reaction (PCR) positive result and within 7 days of the 1st PCR positive result for SARS-CoV-2. (The latest PCR could be the only PCR result.), AND,~3. within 10 days of onset of any COVID-19 symptoms.~Exclusion Criteria:~1. Subject has a concomitant bacterial respiratory infection unless cleared by the Sponsor~2. Subject has a history of abnormalities of uric acid metabolism unless cleared by the Sponsor.~3. Subject has a history of hypersensitivity to an anti-viral nucleoside analog drug targeting a viral RNA polymerase~4. Subject is using adrenocorticosteroids (except topical or inhaled preparations or oral preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers). Dexamethasone 6 mg daily (PO or IV) for 10 days is permitted.~5. Subject has a serious chronic disease (e.g., human immunodeficiency virus (HIV), cancer requiring chemotherapy within the preceding 6 months, moderate or severe hepatic insufficiency and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days).~6. Has previously received favipiravir within the past 30 days~7. Has renal insufficiency requiring hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) or glomerular filtration rate of less than 20 mL/min.~8. Has liver impairment greater than Child-Pugh A.~9. Has a history of alcohol or drug abuse in the previous 6 months.~10. Has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.~11. Has taken another investigational drug within the past 30 days.~12. Is on another antiviral or is participating in another clinical trial for the treatment of COVID-19~13. Subject is on a ventilator at the time of study entry~14. Is deemed by the Investigator to be ineligible for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Favipiravir Treatment Arm (Type: EXPERIMENTAL): Day 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2-14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2-14: 800 mg BID plus SOC
- Standard of Care Arm (Type: OTHER): Standard of Care for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* New or preexisting diagnosis of multiple myeloma~  - Smoldering or indolent multiple myeloma meeting one of the following criteria:~ * Bone marrow plasma cells ≥ 10%~ * Serum monoclonal IgG or IgA protein ≥ 3.0 g/dL OR urine monoclonal light chain ≥ 1g by 24-hour urine protein electrophoresis~* Measurable disease~* Does not require immediate chemotherapy, in the opinion of the treating physician~* No active myeloma or primary amyloidosis requiring chemotherapy or any agents that may interact with anakinra (e.g., etanercept, infliximab, or thalidomide)~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0~* Total WBC ≥ 3,500/mm\^3~* ANC ≥ 1,700/mm\^3~* Creatinine ≤ 1.5 times upper limit of normal~* Able to self-inject medication or have a caregiver who can administer the drug~* Not pregnant or nursing~* Negative pregnancy test~* No acute or chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy within the past 12 weeks~* No active malignancy within the past 5 years except basal cell carcinoma of the skin or carcinoma in situ of cervix~  - Patients with a previously resected malignancy that does not require further treatment are eligible~* No New York Heart Association (NYHA) class III or IV congestive heart failure~* No rheumatoid arthritis or other diseases requiring immunosuppressive therapy~* No asthma, inflammatory bowel disease, or any debilitating physical or psychiatric illness that, in the judgment of the investigator, would interfere with the conduct of the study~PRIOR CONCURRENT THERAPY:~\* More than 30 days since prior treatment with dehydroepiandrosterone (DHEA), clarithromycin, pamidronate, steroids, or any other agent that may affect M-protein

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra with/without Dexamethasone (Type: EXPERIMENTAL): Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete